Albemarle Corporation (ALB)
NYSEMaterialsSpecialty ChemicalsSnapshot 2026-07-09
$128.37-0.78%
Close 2026-07-09 · 1-day change
Reading ALB? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ALB free→NYSEMaterialsSpecialty ChemicalsSnapshot 2026-07-09
Reading ALB? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ALB free→Intact: The reason to own it still holds.
Albemarle is recovering with revenue growing from $1.1B in 2025-Q1 to $1.4B in 2026-Q1. Adjusted EBITDA rose from $267M to $664M in the same period. The company plans to keep capital spending flat around $550M to $600M in 2026. These show progress toward stabilizing and improving profitability.
Albemarle remains volatile and loss-making with a high PE of 55. Margins and earnings have been inconsistent, with recent misses and a sharp stock selloff. The turnaround may stall if revenue growth or EBITDA targets are not sustained.
The market prices in about 11% revenue growth and values the stock roughly 15% below our fair value of $152. Our fair value is 38% below the Street median, reflecting caution on profitability and execution risks.
Breaks if: Adjusted EBITDA falls below $900 million in FY26
Albemarle aims to achieve an adjusted EBITDA target of $0.9 to $1.0 billion for 2026.
Standing thesis, reviewed periodically — not a price target or advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 2 of last 2 quarters. Adjusted EBITDA increased from $267 million in 2025-Q1 to $664 million in 2026-Q1. The trajectory indicates progress towards achieving the adjusted EBITDA target.
“Adjusted EBITDA $0.9 - $1.0 billion for 2026.”
“Adjusted EBITDA (b) $0.9 - $1.0 billion.”
Breaks if: Capital expenditures exceed $600 million or fall below $550 million in FY26
Albemarle plans to maintain capital expenditures flat at $550 million to $600 million for 2026.
Stated in 2 of last 2 quarters. Capital expenditures were $99 million in 2026-Q1, aligning with the flat capex guidance. The trajectory is consistent with maintaining the stated capex range.
“Maintaining full-year capital expenditure forecast of $550 million to $600 million.”
“Capital expenditures to be roughly flat compared to 2025, in the range of $550 million to $600 million.”
Breaks if: Annual revenue falls below $4.1 billion in FY26
Albemarle aims to maintain its revenue guidance for 2026 between $4.1 billion and $4.3 billion.
Stated in 2 of last 2 quarters. Revenue grew from $1.1 billion in 2025-Q1 to $1.4 billion in 2026-Q1. The trajectory shows delivering on maintaining revenue guidance, aligning with the stated range.
“Albemarle expects net sales of $4.1 - $4.3 billion for 2026.”
“Net sales $4.1 - $4.3 billion.”